8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Aplicación de somatotropina recombinante porcina en lechones durante la primera semana de vida: efecto sobre variables metabólicas y somatométricas Translated title: Porcine recombinant somatotropin administered to piglets during the first week of life: effects on metabolic and somatometric variables

      rapid-communication

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Con el fin de evaluar el efecto de la administración de la somatotropina recombinante porcina (rpST) en lechones, sobre las variables metabólicas y somatométricas durante la primera semana de vida, se evaluaron un total de 220 lechones al nacimiento de 40 cerdas híbridas Landrace x Large White. Los lechones fueron clasificados aleatoriamente en dos grupos. El Grupo 1 conformado por 106 lechones (Grupo testigo) y el grupo 2 por un total de 114 lechones (Grupo tratado con pST). La administración de la rpST se realizó a una dosis de 1 mg/kg cada 24 h durante siete días. En el pH al nacimiento se apreciaron diferencias significativas (P < 0,05) en ambos grupos (7,42 ± 0,47 y 7,31 ± 0,59), fenómeno que desaparece a la semana de vida. A la semana se observó un aumento significativo (P < 0,001) en los niveles de glucosa en los lechones del G2 vs. G1 (103,71 ± 18,4468, 78 ± 10,44). Al final del experimento la ganancia diaria de peso fue mayor para el grupo tratado con rpST (209,21 ± 45,97) respecto al grupo testigo (137,25 ± 31,31). Al comparar el efecto del tratamiento por sexo se observaron marcadas diferencias significativas (P < 0,001) en el pH, glucosa, lactato y peso ganado en los machos del G2 con respecto a las hembras del mismo grupo a los siete días postratamiento. Los lechones tratados con rpST presentaron diferencias significativas en las variables: perímetro abdominal (28,67 ± 4,41 y 31,79 ± 3,74 respectivamente), largo dorsal (28,42 ± 2,66 y 30,21 ± 4,70 respectivamente) y redondez del jamón (18,79 ± 2,62 y 22,38 ± 2,98 respectivamente). Investigación en proceso permitirá distinguir la masa corporal ganada por los lechones, en ósea o muscular.

          Translated abstract

          The aim of this study was to evaluate the effect of porcine recombinant somatotropin (rpST) administered to piglets during their first week of life, on metabolic and somatometric variables. A total of 220 piglets born from 40 hybrid Landrace x Large White sows were used. Piglets were randomly assigned to either Group 1 (G1, Control, n = 106) or Group 2 (G2, rpST treatment, n = 114). The rpST dose was 1mg/kg every 24h during 7 consecutive days. Serum pH at birth showed significant differences between groups (7.42 ± 0.47 and 7.31 ± 0.59), although this difference dissapeared on day 8. There was a significant increase (P < 0,001) in plasma glucose levels for the treated group on day 8 (68.78 ± 10.44 and 103.71 ± 18.44). Average daily weight gain was also higher for the somatotropin treated group compared to the control (137.25 ± 31.31 and 209.21 ± 45.97). Comparisons for interaction between treatment and sex showed dramatic differences (P < 0,001) for glucose, lactate and weight gain for the males from G2 when compared to the females from the same experimental group on day 7 post-treatment. Piglets treated with rpST showed significant differences in abdominal perimeter (28.67 ± 4.41 and 31.79 ± 3.74), dorsal length (28.42 ± 2.66 and 30.21 ± 4.70), and ham roundness (18.79 ± 2.62 and 22.38 ± 2.98). There is an ongoing research that will allow to determine the composition of body mass (bone or muscle) in the treated piglets.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation.

          Circulating IGF-I and -II are bound to specific insulin-like growth factor (IGF)-binding proteins (IGFBPs), of which IGFBP-3 binds the majority of the IGFs. IGFBP-3 levels are regulated by GH and have been suggested to provide additional information on GH secretory capacity compared to IGF-I. However, the diagnostic value of IGFBP-3 is still controversial, perhaps because the quality of the available normative data for IGFBP-3 varies. It has recently been shown that a large number of individuals is required to establish reference ranges for IGF-I that take into account age, sex, body mass index (BMI), and pubertal stage. Therefore, we measured IGFBP-3, IGF-I, IGF-II, IGFBP-1, and IGFBP-2 levels by RIA in 907 healthy children to establish well characterized normative data on IGFBP-3 according to age, sex, and pubertal stage and to study the complex relationship between IGFs and their BPs in puberty. We found that IGFBP-3 levels increase with age in children, with maximal levels in puberty; girls experience peak values approximately 1 yr earlier than boys. Age, sex, height, BMI, and pubertal maturation were all important factors in determining the circulating levels of IGFBP-3, whereas IGF-I levels were unaffected by BMI. Comparison of IGFBP-3 with IGF-1 concentrations revealed that they did not exhibit the same developmental pattern in puberty. IGF-I levels increased to relatively higher levels than IGFBP-3, leading to an increasing molar ratio between IGF-I and IGFBP-3 in puberty, when growth velocity is high. Concomitantly, IGF-II and IGFBP-2 levels were unchanged throughout puberty, whereas IGFBP-1 levels declined with age in prepubertal children, with lowest values in puberty. There was a highly significant correlation between IGF-I and -II and IGFBP-3 on a molar basis (r = 0.84; P < 0.0001). Thus, we speculate that IGFBP-3 is pivotal for circulating IGF bioactivity and that the increase in the molar ratio between IGF-I and IGFBP-3 reflects an increase in free, biologically active IGF-I. In conclusion, we have provided normative data on a large group of healthy individuals and conclude that age, sex, height, BMI, and pubertal maturation have to be taken into account before a single IGFBP-3 value in a growth-retarded child can be evaluated properly.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Guidelines for the ethical use of animals in applied ethology studies

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro.

              Androgens stimulate bone formation and play an important role in the maintenance of bone mass. Clinical observations suggest that both gonadal and adrenal androgens contribute to the positive impact of androgenic steroids on bone metabolism. We investigated the mechanism of action of the adrenal androgen dehydroepiandrosterone (DHEA) and its sulfated compound dehydroepiandrosterone sulfate (DHEAS) on human osteoblastic cells (HOCs) in vitro. The DHEA- and DHEAS-induced effects were analyzed in parallel with the actions elicited by the gonadal androgen dihydrotestosterone (DHT). There was no qualitative difference between the effects of gonadal and adrenal androgens on HOC metabolism in vitro. Both were stimulatory as regards cell proliferation and differentiated functions, but the gonadal androgen DHT was significantly more potent than DHEA. The actions of DHT and DHEA on HOC proliferation and alkaline phosphatase (ALP) production could be prevented by the androgen receptor antagonist hydroxyflutamide and inhibitory transforming growth factor beta antibodies (TGF-beta ab), respectively, but were not affected by the presence of the 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) and 5-alpha-reductase (5-AR) inhibitor 17 beta-N,N-diethylcarbamoyl-4-methyl- 4aza-5 alpha-androstan-3-one (4-MA). This indicates that DHT and DHEA (1) exert their mitogenic effects by androgen receptor-mediated mechanisms, (2) stimulate ALP production by increased TGF-beta expression, (3) that the action of DHT is not affected by the presence of 4-MA, and that (4) DHEA does not need to be metabolized by 3 beta HSD or 5-AR first to exert its effects on HOCs in vitro.
                Bookmark

                Author and article information

                Journal
                amv
                Archivos de medicina veterinaria
                Arch. med. vet.
                Facultad de Ciencias Veterinarias, Universidad Austral de Chile (Valdivia, , Chile )
                0301-732X
                2010
                : 42
                : 2
                : 93-99
                Affiliations
                [05] México DF orgnameInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán orgdiv1Departamento de Investigación Experimental y Bioterio México
                [04] Teziutlán Puebla orgnameEIAH-Benemérita Universidad Autónoma de Puebla México
                [03] México DF orgnameUniversidad Autónoma Metropolitana-Xochimilco orgdiv1Departamento de Producción Agrícola y Animal México
                [02] México DF orgnameUniversidad Nacional Autónoma de México México
                [01] México DF orgnameUniversidad Autónoma Metropolitana-Xochimilco orgdiv1Programa de Doctorado en Ciencias Biológicas México
                Article
                S0301-732X2010000200011 S0301-732X(10)04200200011
                2a3500b0-c8d8-4c88-ad5f-4ee10e0bb53c

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 28, Pages: 7
                Product

                SciELO Chile

                Categories
                COMUNICACIONES

                porcine recombinant somatotropin,peso,vitalidad neonatal,lechón,somatotropina recombinante porcina,weight,neonatal vitality,piglet

                Comments

                Comment on this article